M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B BioPharma DiveAssertio s latest offer represents a roughly 31% premium over an initial acquisition proposal.Read full story pharminent May 13, 2026 (Last updated: May 13, 2026) BioPharma Dive Assertio s latest offer represents a roughly 31% premium over an initial acquisition proposal. Read full story Post navigation Previous: Previous PostNext: UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged Related Stories M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026 M&A / Deals Lilly, Gilead lead pharma’s M&A boom pharminent May 8, 2026
